Section Arrow
SNDX.NASDAQ
- Syndax Pharmaceuticals
Quotes are at least 15-min delayed:2025/09/12 04:14 EDT
Pre Market
Last
 --
-- (--)
Bid
16.26
Ask
22
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 16.37
+0.64 (+4.07%)
Day High 
16.47 
Prev. Close
15.73 
1-M High
17.24 
Volume 
1.87M 
Bid
16.26
Ask
22
Day Low
15.59 
Open
15.77 
1-M Low
12.1 
Market Cap 
1.36B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 16.24 
20-SMA 15.84 
50-SMA 12.47 
52-W High 22.5 
52-W Low 8.58 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.89/-1.32
Enterprise Value
1.69B
Balance Sheet
Book Value Per Share
1.83
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
23.68M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GRIGRI Bio Inc.2.05+0.49+31.41%0.02PE
Pre Market 1.78 -0.27 -13.17%
RXRXRecursion Pharmaceuticals4.85+0.31+6.83%-- 
Pre Market 4.93 +0.08 +1.65%
SLXNSilexion Therapeutics Corp4.93+0.445+9.92%-- 
Pre Market 4.92 -0.01 -0.20%
ADAPAdaptimmune Therapeutics plc0.0505-0.0003-0.59%-- 
Pre Market 0.0515 +0.001 +1.98%
ROIVRoivant Sciences Ltd14.41+0.64+4.65%1.95PE
Pre Market 14.41 0 0.00%
Quotes are at least 15-min delayed:2025/09/12 04:14 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.